Condition: Platinum-resistant Ovarian Cancer · Recurrent Ovary Cancer · Ovarian Cancer · Sponsor: Dana-Farber Cancer Institute
The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
This description comes directly from the study's public registry record.
DFCI Clinical Trials Hotline DFCI Clinical Trials Hotline · 877-DF-TRIAL · rebecca_porter@dfci.harvard.edu
Rebecca Porter, MD, PhD · (617) 632-5269 · rebecca_porter@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06321484